Promising novel agents for aggressive B-cell lymphoma Journal Article
| Author: | Younes, A. |
| Article Title: | Promising novel agents for aggressive B-cell lymphoma |
| Abstract: | Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoma in the western world. Current treatment regimens result in curing approximately 50% to 60% of patients with DLBCL. In 2006, the Food and Drug Administration approved rituximab for use in the first-line treatment of patients with DLBCL in combination with anthracycline-based chemotherapy regimens. Since then, no other agents have been approved for the treatment of DLBCL. This article reviews recent data on the most promising agents in development for the treatment of DLBCL. © 2016 Elsevier Inc. |
| Keywords: | diffuse large b-cell lymphoma; b-cell receptor; bcl2 inhibitor; ezh2 inhibitor |
| Journal Title: | Hematology/Oncology Clinics of North America |
| Volume: | 30 |
| Issue: | 6 |
| ISSN: | 0889-8588 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2016-12-01 |
| Start Page: | 1229 |
| End Page: | 1237 |
| Language: | English |
| DOI: | 10.1016/j.hoc.2016.07.007 |
| PROVIDER: | scopus |
| PUBMED: | 27888877 |
| PMCID: | PMC5576035 |
| DOI/URL: | |
| Notes: | Review -- Export Date: 3 January 2017 -- Source: Scopus |
